Loading..

BioNTech SE (BNTX) Q3 2021 Report Analysis


Company Overview

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Company Highlights


Parameter Value Change Score
Assets 14,232.6 56% 40
Capital Expenditure -110.79 -23% 52
Cash & Equivalents 2,392.7 162% 97
Equity 8,711.5 59% 77
Liabilities 5,521.1 51% 40
EBITDA 10,300.84 85% 63
Total Revenues 13,789.62 77% 40
Parameter Value Change Score
Free Cashflow 4.92 352% 97
Cashflow 1,402.16 311% 93
Asset Turnover 1.76 15% 64
Price to Book 6.31 -25% 72
Return on Equity 155.47 16% 72

* All values are TTM

Report Summary

Our analysis and prediction of BioNTech SE's expected performance over the coming months is based on a thorough AI-powered analysis of their financial statement. In addition, a number of particular general factors and ratios were also utilized. First, assessing the balance sheet factors followed closely to the benchmark. Second, the income statement performance metrics followed closely to the benchmark in the above time frame. Next, cash flow metrics over-performed the market benchmark significantly. Fourth, the most historically impactful financial ratios forecast that in the near term the company's growth will just keep up with their benchmark. With all factors taken together, our bottom line grade for BioNTech SE received a cumulative score of 65.

The below chart reflects BioNTech SE's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While BioNTech SE's peer average final assessment score stands on 58, BioNTech SE's score is 65 out of 100.

  •  BNTX
  •  Peers average
Name Market Cap Balance Sheet Income Statement Cash Flow General Factors Final Assessment mc_sort Hidden
Johnson & Johnson 438.5B 63 70 76 73 67 0 1
Pfizer Inc. 300.5B 63 60 78 81 68 1 1
AstraZeneca PLC 181.5B 61 77 71 68 64 2 1
Amgen Inc. 130.3B 74 70 53 54 63 3 1
Gilead Sciences, Inc. 86.6B 78 58 88 75 81 4 1
Moderna, Inc. 70.6B 61 59 86 65 62 5 1
Regeneron Pharmaceuticals, Inc. 64.6B 74 64 96 69 79 6 1
Vertex Pharmaceuticals Incorporated 58.7B 82 67 81 74 85 7 1
Biogen Inc. 33.9B 68 77 55 73 66 8 1
BeiGene, Ltd. 24.3B 53 62 69 69 52 9 1
Seagen Inc. 24.2B 45 75 48 74 44 10 1
Horizon Therapeutics Public Limited Company 20.0B 71 69 90 68 76 11 1
Alnylam Pharmaceuticals, Inc. 16.6B 51 67 56 75 49 12 1
Incyte Corporation 16.5B 68 61 85 72 71 13 1
BioMarin Pharmaceutical Inc. 15.8B 58 90 76 74 67 14 1
United Therapeutics Corporation 9.2B 67 72 54 73 64 15 1
Novavax, Inc. 7.0B 49 73 54 79 50 16 1
Neurocrine Biosciences, Inc. 6.9B 66 50 79 86 69 17 1
Ascendis Pharma A/S 6.7B 53 60 67 68 50 18 1
Mirati Therapeutics, Inc. 6.7B 71 63 76 55 66 19 1
Legend Biotech Corporation 6.2B 47 73 77 81 55 20 1
Natera, Inc. 5.8B 70 67 49 51 56 21 1
Arena Pharmaceuticals, Inc. 5.6B 66 79 64 69 67 22 1
Arrowhead Pharmaceuticals, Inc. 5.6B 70 67 59 68 65 23 1
Sarepta Therapeutics, Inc. 5.5B 67 63 80 64 66 24 1
Exelixis, Inc. 5.4B 63 61 76 76 65 25 1
Halozyme Therapeutics, Inc. 4.7B 89 57 88 64 88 26 1
Ultragenyx Pharmaceutical Inc. 4.5B 53 61 71 75 54 27 1
Vir Biotechnology, Inc. 4.4B 58 41 60 85 54 28 1
Ionis Pharmaceuticals, Inc. 4.3B 70 69 54 59 61 29 1
Blueprint Medicines Corporation 4.3B 63 75 55 53 54 30 1
Beam Therapeutics Inc. 4.2B 80 53 70 57 71 31 1
Denali Therapeutics Inc. 4.1B 55 74 70 68 56 32 1
Alkermes plc 4.0B 55 72 76 75 61 33 1
Apellis Pharmaceuticals, Inc. 3.7B 87 78 52 55 77 34 1
NantKwest, Inc. 3.6B 44 64 64 72 44 35 1
ACADIA Pharmaceuticals Inc. 3.5B 75 66 79 62 73 36 1
OPKO Health, Inc. 3.0B 80 61 46 66 68 37 1
PTC Therapeutics, Inc. 2.9B 47 70 63 80 51 38 1
Twist Bioscience Corporation 2.7B 52 66 94 67 58 39 1
Cytokinetics, Incorporated 2.7B 60 73 42 53 47 40 1
SpringWorks Therapeutics, Inc. 2.6B 46 71 57 81 48 41 1
Insmed Incorporated 2.6B 47 69 67 76 50 42 1
BioCryst Pharmaceuticals, Inc. 2.6B 45 70 71 82 52 43 1
ImmunityBio, Inc. 2.4B 63 72 61 75 64 44 1
Myriad Genetics, Inc. 2.1B 77 38 85 61 70 45 1
Recursion Pharmaceuticals, Inc. 2.1B 45 44 75 71 42 46 1
ChemoCentryx, Inc. 2.1B 58 66 68 87 64 47 1
Ironwood Pharmaceuticals, Inc. 1.8B 64 72 68 61 61 48 1
Turning Point Therapeutics, Inc. 1.8B 48 73 50 65 43 49 1
Global Blood Therapeutics, Inc. 1.8B 58 68 54 72 55 50 1
Revolution Medicines, Inc. 1.8B 53 73 70 70 55 51 1
BridgeBio Pharma, Inc. 1.7B 78 71 75 74 81 52 1
Agios Pharmaceuticals, Inc. 1.7B 79 62 71 78 80 53 1
Prothena Corporation plc 1.7B 79 58 78 58 73 54 1
Sana Biotechnology, Inc. 1.7B 41 49 69 83 42 55 1
Allogene Therapeutics, Inc. 1.7B 53 70 69 73 55 56 1
Instil Bio, Inc. 1.6B 46 50 64 80 45 57 1
Verve Therapeutics, Inc. 1.6B 44 45 69 79 43 58 1
IVERIC bio, Inc. 1.5B 80 68 49 69 72 59 1
Bicycle Therapeutics plc 1.4B 54 66 88 82 64 60 1
Erasca, Inc. 1.4B 68 46 56 67 57 61 1
Editas Medicine, Inc. 1.3B 84 73 72 42 74 62 1
Atara Biotherapeutics, Inc. 1.3B 55 62 62 74 54 63 1
Lyell Immunopharma, Inc. 1.3B 65 47 75 68 60 64 1
Prometheus Biosciences, Inc. 1.3B 67 44 67 66 59 65 1
Alector, Inc. 1.3B 56 59 77 59 53 66 1
ImmunoGen, Inc. 1.3B 80 71 61 64 74 67 1
FibroGen, Inc. 1.2B 80 67 89 61 81 68 1
C4 Therapeutics, Inc. 1.2B 57 51 72 76 56 69 1
Enanta Pharmaceuticals, Inc. 1.2B 50 66 91 86 63 70 1
Madrigal Pharmaceuticals, Inc. 1.2B 42 70 67 76 45 71 1
REGENXBIO Inc. 1.1B 48 73 70 76 53 72 1
Anavex Life Sciences Corp. 1.0B 50 54 94 72 55 73 1
Replimune Group, Inc. 998.4M 53 69 60 74 53 74 1
Vaxcyte, Inc. 974.7M 46 72 46 74 43 75 1
Crinetics Pharmaceuticals, Inc. 960.1M 54 70 56 78 54 76 1
Day One Biopharmaceuticals, Inc. 911.0M 57 43 69 76 53 77 1
Syndax Pharmaceuticals, Inc. 893.8M 52 61 64 87 56 78 1
AnaptysBio, Inc. 891.3M 64 59 88 82 71 79 1
Immunocore Holdings plc 889.6M 64 69 56 76 62 80 1
Inovio Pharmaceuticals, Inc. 881.5M 68 76 74 64 69 81 1
Sangamo Therapeutics, Inc. 877.0M 66 73 45 64 57 82 1
uniQure N.V. 860.5M 60 64 67 68 57 83 1
Kura Oncology, Inc. 848.6M 58 69 64 70 57 84 1
MacroGenics, Inc. 811.7M 64 71 82 61 65 85 1
Centessa Pharmaceuticals Limited 802.8M 52 69 52 72 49 86 1
Immunovant, Inc. 802.7M 65 69 70 63 62 87 1
Gossamer Bio, Inc. 789.5M 44 73 65 83 50 88 1
Arcutis Biotherapeutics, Inc. 785.6M 46 68 65 76 48 89 1
PMV Pharmaceuticals, Inc. 772.4M 52 54 76 70 51 90 1
Design Therapeutics, Inc. 772.1M 45 66 57 80 46 91 1
Kiniksa Pharmaceuticals, Ltd. 763.3M 66 64 81 69 67 92 1
Chinook Therapeutics, Inc. 749.8M 56 50 64 72 51 93 1
Century Therapeutics, Inc. 745.4M 63 47 70 71 58 94 1
MeiraGTx Holdings plc 732.5M 57 69 64 84 61 95 1
Rubius Therapeutics, Inc. 705.4M 50 69 64 71 50 96 1
COMPASS Pathways plc 696.9M 49 51 81 80 53 97 1

Balance Sheet Analysis

Analysis of the balance sheet underlined certain key metrics that provide some of the most meaningful signals into forecasting performance for the next 3 months or longer. Typically, the balance sheet factors affect roughly up to 46.3% of the likelihood that a company will over-perform its benchmark during the coming months. In particular, looking at BioNTech SE's debt service capabilities shows excellent results concerning cash and cash equivalents. Historically, the debt service capabilities factors will influence up to 3.0% of the likelihood that the company will over-perform the market. Second, their assets indicates lackluster momentum with respect to assets changes. The strength of a company's assets contribute up to 19.5% of the probability that a company will over-perform. Reviewing the company's debt structure reveals sub-par results with respect to liabilities movement. Typically, the debt structure factors influence approximately up to 19.5% of a company's likelihood to over-perform. Moreover, the company's forecasts positive overperformance in terms of shareholders' equity and intangible assets adjustments. Intangible assets and technical changes contribute roughly 4.3% of a company's likelihood to over-perform its benchmark during the coming months. With all these factors considered, their balance sheet warranted a score of 60.

Parameter Value Change Score
Assets 14,232.6 56% 40
Capital Expenditure -110.79 -23% 52
Cash & Equivalents 2,392.7 162% 97
Equity 8,711.5 59% 77
Liabilities 5,521.1 51% 40
* All values are TTM

The below chart describes BioNTech SE's performance as reflected on its balance sheet with respect to its peers. While BioNTech SE received a balance sheet score of 60 out of 100, the average of its peers stands on 59 out of 100.

  •  BNTX
  •  Peers average
Name Market Cap Liabilities Movement Asset Change Equity/Intangibles Adjustments Cash & Equivalents Capital Expenditure Growth Balance Sheet mc_sort Hidden
Johnson & Johnson 438.5B 55 55 68 87 71 63 0 1
Pfizer Inc. 300.5B 52 52 74 50 66 63 1 1
AstraZeneca PLC 181.5B 58 58 65 38 68 61 2 1
Amgen Inc. 130.3B 66 66 80 94 56 74 3 1
Gilead Sciences, Inc. 86.6B 77 77 76 56 80 78 4 1
Moderna, Inc. 70.6B 53 53 71 68 41 61 5 1
Regeneron Pharmaceuticals, Inc. 64.6B 76 76 68 93 81 74 6 1
Vertex Pharmaceuticals Incorporated 58.7B 66 66 90 74 94 82 7 1
Biogen Inc. 33.9B 54 54 78 55 87 68 8 1
BeiGene, Ltd. 24.3B 66 66 46 47 50 53 9 1
Seagen Inc. 24.2B 39 39 47 93 81 45 10 1
Horizon Therapeutics Public Limited Company 20.0B 74 74 68 89 56 71 11 1
Alnylam Pharmaceuticals, Inc. 16.6B 59 59 45 91 53 51 12 1
Incyte Corporation 16.5B 54 54 77 81 85 68 13 1
BioMarin Pharmaceutical Inc. 15.8B 53 53 62 65 69 58 14 1
United Therapeutics Corporation 9.2B 69 69 67 65 54 67 15 1
Novavax, Inc. 7.0B 61 61 40 61 66 49 16 1
Neurocrine Biosciences, Inc. 6.9B 66 66 68 51 46 66 17 1
Ascendis Pharma A/S 6.7B 39 39 65 94 46 53 18 1
Mirati Therapeutics, Inc. 6.7B 97 97 51 53 63 71 19 1
Legend Biotech Corporation 6.2B 60 60 38 43 61 47 20 1
Natera, Inc. 5.8B 73 73 69 92 43 70 21 1
Arena Pharmaceuticals, Inc. 5.6B 94 94 45 45 65 66 22 1
Arrowhead Pharmaceuticals, Inc. 5.6B 89 89 51 40 95 70 23 1
Sarepta Therapeutics, Inc. 5.5B 89 89 45 62 90 67 24 1
Exelixis, Inc. 5.4B 63 63 63 84 57 63 25 1
Halozyme Therapeutics, Inc. 4.7B 78 78 98 80 54 89 26 1
Ultragenyx Pharmaceutical Inc. 4.5B 62 62 50 43 50 53 27 1
Vir Biotechnology, Inc. 4.4B 44 44 73 65 42 58 28 1
Ionis Pharmaceuticals, Inc. 4.3B 83 83 55 82 94 70 29 1
Blueprint Medicines Corporation 4.3B 84 84 48 75 43 63 30 1
Beam Therapeutics Inc. 4.2B 95 95 66 97 63 80 31 1
Denali Therapeutics Inc. 4.1B 66 66 49 49 53 55 32 1
Alkermes plc 4.0B 50 50 57 85 83 55 33 1
Apellis Pharmaceuticals, Inc. 3.7B 98 98 72 76 97 87 34 1
NantKwest, Inc. 3.6B 46 46 45 37 40 44 35 1
ACADIA Pharmaceuticals Inc. 3.5B 87 87 63 37 94 75 36 1
OPKO Health, Inc. 3.0B 87 87 67 95 98 80 37 1
PTC Therapeutics, Inc. 2.9B 46 46 49 78 60 47 38 1
Twist Bioscience Corporation 2.7B 53 53 48 66 96 52 39 1
Cytokinetics, Incorporated 2.7B 46 46 72 96 44 60 40 1
SpringWorks Therapeutics, Inc. 2.6B 46 46 49 81 46 46 41 1
Insmed Incorporated 2.6B 52 52 45 58 59 47 42 1
BioCryst Pharmaceuticals, Inc. 2.6B 52 52 42 63 56 45 43 1
ImmunityBio, Inc. 2.4B 87 87 41 46 97 63 44 1
Myriad Genetics, Inc. 2.1B 96 96 63 96 37 77 45 1
Recursion Pharmaceuticals, Inc. 2.1B 44 44 50 41 49 45 46 1
ChemoCentryx, Inc. 2.1B 61 61 54 86 69 58 47 1
Ironwood Pharmaceuticals, Inc. 1.8B 62 62 69 84 37 64 48 1
Turning Point Therapeutics, Inc. 1.8B 46 46 54 63 41 48 49 1
Global Blood Therapeutics, Inc. 1.8B 71 71 47 58 77 58 50 1
Revolution Medicines, Inc. 1.8B 53 53 53 42 81 53 51 1
BridgeBio Pharma, Inc. 1.7B 92 92 70 39 41 78 52 1
Agios Pharmaceuticals, Inc. 1.7B 84 84 72 38 97 79 53 1
Prothena Corporation plc 1.7B 95 95 67 92 41 79 54 1
Sana Biotechnology, Inc. 1.7B 41 41 44 41 65 41 55 1
Allogene Therapeutics, Inc. 1.7B 52 52 52 52 93 53 56 1
Instil Bio, Inc. 1.6B 42 42 54 37 51 46 57 1
Verve Therapeutics, Inc. 1.6B 39 39 50 38 77 44 58 1
IVERIC bio, Inc. 1.5B 95 95 65 97 74 80 59 1
Bicycle Therapeutics plc 1.4B 43 43 63 89 65 54 60 1
Erasca, Inc. 1.4B 53 53 82 97 37 68 61 1
Editas Medicine, Inc. 1.3B 94 94 76 46 61 84 62 1
Atara Biotherapeutics, Inc. 1.3B 74 74 43 58 43 55 63 1
Lyell Immunopharma, Inc. 1.3B 82 82 50 43 78 65 64 1
Prometheus Biosciences, Inc. 1.3B 93 93 50 58 43 67 65 1
Alector, Inc. 1.3B 38 38 71 97 55 56 66 1
ImmunoGen, Inc. 1.3B 87 87 68 74 94 80 67 1
FibroGen, Inc. 1.2B 89 89 76 47 52 80 68 1
C4 Therapeutics, Inc. 1.2B 63 63 51 40 89 57 69 1
Enanta Pharmaceuticals, Inc. 1.2B 44 44 49 98 98 50 70 1
Madrigal Pharmaceuticals, Inc. 1.2B 45 45 41 91 41 42 71 1
REGENXBIO Inc. 1.1B 53 53 47 55 55 48 72 1
Anavex Life Sciences Corp. 1.0B 49 49 50 65 74 50 73 1
Replimune Group, Inc. 998.4M 58 58 52 50 53 53 74 1
Vaxcyte, Inc. 974.7M 49 49 48 45 46 46 75 1
Crinetics Pharmaceuticals, Inc. 960.1M 66 66 46 57 60 54 76 1
Day One Biopharmaceuticals, Inc. 911.0M 43 43 67 64 74 57 77 1
Syndax Pharmaceuticals, Inc. 893.8M 60 60 44 76 74 52 78 1
AnaptysBio, Inc. 891.3M 73 73 55 72 66 64 79 1
Immunocore Holdings plc 889.6M 74 74 52 59 94 64 80 1
Inovio Pharmaceuticals, Inc. 881.5M 79 79 56 84 86 68 81 1
Sangamo Therapeutics, Inc. 877.0M 84 84 50 75 65 66 82 1
uniQure N.V. 860.5M 78 78 49 53 44 60 83 1
Kura Oncology, Inc. 848.6M 66 66 51 71 66 58 84 1
MacroGenics, Inc. 811.7M 82 82 50 72 51 64 85 1
Centessa Pharmaceuticals Limited 802.8M 48 48 60 62 43 52 86 1
Immunovant, Inc. 802.7M 41 41 82 91 68 65 87 1
Gossamer Bio, Inc. 789.5M 52 52 42 41 57 44 88 1
Arcutis Biotherapeutics, Inc. 785.6M 41 41 52 40 68 46 89 1
PMV Pharmaceuticals, Inc. 772.4M 53 53 54 61 42 52 90 1
Design Therapeutics, Inc. 772.1M 39 39 55 65 37 45 91 1
Kiniksa Pharmaceuticals, Ltd. 763.3M 91 91 46 82 50 66 92 1
Chinook Therapeutics, Inc. 749.8M 75 75 45 48 39 56 93 1
Century Therapeutics, Inc. 745.4M 85 85 49 38 43 63 94 1
MeiraGTx Holdings plc 732.5M 71 71 49 50 51 57 95 1
Rubius Therapeutics, Inc. 705.4M 49 49 51 61 65 50 96 1
COMPASS Pathways plc 696.9M 47 47 54 60 46 49 97 1

Income Statement Analysis

Analyzing the the company's income statement focused our attention on several specific results that typically have the greatest effect on company performance for the near term. Specifically, their net income signals standard execution going into earnings movement. Generally, a company's net income affects roughly 6.6% of a company's likelihood to beat the market Further, the company's cost of sales found neutral execution going into capital expenditure growth. In general, the Company's cost of sales affect 4.0% of the likelihood that a company will over-perform the market. Looking at their revenue indicates lackluster momentum in terms of revenue momentum. Revenue momentum will influence up to 2.6% of the chances of the company to beat the market throughout the upcoming quarter. In summary, our evaluation of the company's income statement gave the score of 59.

Parameter Value Change Score
EBITDA 10,300.84 85% 63
Total Revenues 13,789.62 77% 40
* All values are TTM

The below chart describes BioNTech SE's performance as reflected on its income statement with respect to its peers. While BioNTech SE received a income statement score of 59 out of 100, the average of its peers stands on 63 out of 100.

  •  BNTX
  •  Peers average
Name Market Cap Revenue Momentum Earning Movement Income Statement mc_sort Hidden
Johnson & Johnson 438.5B 67 71 70 0 1
Pfizer Inc. 300.5B 43 63 60 1 1
AstraZeneca PLC 181.5B 48 80 77 2 1
Amgen Inc. 130.3B 74 70 70 3 1
Gilead Sciences, Inc. 86.6B 64 58 58 4 1
Moderna, Inc. 70.6B 40 62 59 5 1
Regeneron Pharmaceuticals, Inc. 64.6B 50 67 64 6 1
Vertex Pharmaceuticals Incorporated 58.7B 54 69 67 7 1
Biogen Inc. 33.9B 92 75 77 8 1
BeiGene, Ltd. 24.3B 47 65 62 9 1
Seagen Inc. 24.2B 97 72 75 10 1
Horizon Therapeutics Public Limited Company 20.0B 46 72 69 11 1
Alnylam Pharmaceuticals, Inc. 16.6B 51 70 67 12 1
Incyte Corporation 16.5B 54 63 61 13 1
BioMarin Pharmaceutical Inc. 15.8B 91 88 90 14 1
United Therapeutics Corporation 9.2B 61 73 72 15 1
Novavax, Inc. 7.0B 70 74 73 16 1
Neurocrine Biosciences, Inc. 6.9B 63 50 50 17 1
Ascendis Pharma A/S 6.7B 97 57 60 18 1
Mirati Therapeutics, Inc. 6.7B 37 67 63 19 1
Legend Biotech Corporation 6.2B 58 74 73 20 1
Natera, Inc. 5.8B 47 70 67 21 1
Arena Pharmaceuticals, Inc. 5.6B 97 76 79 22 1
Arrowhead Pharmaceuticals, Inc. 5.6B 98 64 67 23 1
Sarepta Therapeutics, Inc. 5.5B 53 65 63 24 1
Exelixis, Inc. 5.4B 52 63 61 25 1
Halozyme Therapeutics, Inc. 4.7B 47 60 57 26 1
Ultragenyx Pharmaceutical Inc. 4.5B 77 60 61 27 1
Vir Biotechnology, Inc. 4.4B 41 44 41 28 1
Ionis Pharmaceuticals, Inc. 4.3B 92 66 69 29 1
Blueprint Medicines Corporation 4.3B 99 72 75 30 1
Beam Therapeutics Inc. 4.2B 37 56 53 31 1
Denali Therapeutics Inc. 4.1B 89 72 74 32 1
Alkermes plc 4.0B 67 73 72 33 1
Apellis Pharmaceuticals, Inc. 3.7B 69 78 78 34 1
NantKwest, Inc. 3.6B 39 69 64 35 1
ACADIA Pharmaceuticals Inc. 3.5B 68 66 66 36 1
OPKO Health, Inc. 3.0B 90 59 61 37 1
PTC Therapeutics, Inc. 2.9B 60 72 70 38 1
Twist Bioscience Corporation 2.7B 98 63 66 39 1
Cytokinetics, Incorporated 2.7B 97 70 73 40 1
SpringWorks Therapeutics, Inc. 2.6B 82 70 71 41 1
Insmed Incorporated 2.6B 70 69 69 42 1
BioCryst Pharmaceuticals, Inc. 2.6B 41 73 70 43 1
ImmunityBio, Inc. 2.4B 93 69 72 44 1
Myriad Genetics, Inc. 2.1B 64 38 38 45 1
Recursion Pharmaceuticals, Inc. 2.1B 45 46 44 46 1
ChemoCentryx, Inc. 2.1B 40 69 66 47 1
Ironwood Pharmaceuticals, Inc. 1.8B 77 71 72 48 1
Turning Point Therapeutics, Inc. 1.8B 97 70 73 49 1
Global Blood Therapeutics, Inc. 1.8B 51 70 68 50 1
Revolution Medicines, Inc. 1.8B 97 70 73 51 1
BridgeBio Pharma, Inc. 1.7B 95 68 71 52 1
Agios Pharmaceuticals, Inc. 1.7B 82 61 62 53 1
Prothena Corporation plc 1.7B 38 61 58 54 1
Sana Biotechnology, Inc. 1.7B 82 48 49 55 1
Allogene Therapeutics, Inc. 1.7B 77 70 70 56 1
Instil Bio, Inc. 1.6B 82 49 50 57 1
Verve Therapeutics, Inc. 1.6B 82 43 45 58 1
IVERIC bio, Inc. 1.5B 82 67 68 59 1
Bicycle Therapeutics plc 1.4B 60 67 66 60 1
Erasca, Inc. 1.4B 82 45 46 61 1
Editas Medicine, Inc. 1.3B 98 70 73 62 1
Atara Biotherapeutics, Inc. 1.3B 40 66 62 63 1
Lyell Immunopharma, Inc. 1.3B 44 49 47 64 1
Prometheus Biosciences, Inc. 1.3B 41 47 44 65 1
Alector, Inc. 1.3B 37 62 59 66 1
ImmunoGen, Inc. 1.3B 94 68 71 67 1
FibroGen, Inc. 1.2B 40 71 67 68 1
C4 Therapeutics, Inc. 1.2B 77 50 51 69 1
Enanta Pharmaceuticals, Inc. 1.2B 99 63 66 70 1
Madrigal Pharmaceuticals, Inc. 1.2B 82 68 70 71 1
REGENXBIO Inc. 1.1B 97 70 73 72 1
Anavex Life Sciences Corp. 1.0B 82 52 54 73 1
Replimune Group, Inc. 998.4M 82 68 69 74 1
Vaxcyte, Inc. 974.7M 82 71 72 75 1
Crinetics Pharmaceuticals, Inc. 960.1M 82 69 70 76 1
Day One Biopharmaceuticals, Inc. 911.0M 82 41 43 77 1
Syndax Pharmaceuticals, Inc. 893.8M 37 65 61 78 1
AnaptysBio, Inc. 891.3M 44 61 59 79 1
Immunocore Holdings plc 889.6M 90 66 69 80 1
Inovio Pharmaceuticals, Inc. 881.5M 74 76 76 81 1
Sangamo Therapeutics, Inc. 877.0M 96 71 73 82 1
uniQure N.V. 860.5M 77 63 64 83 1
Kura Oncology, Inc. 848.6M 82 68 69 84 1
MacroGenics, Inc. 811.7M 90 69 71 85 1
Centessa Pharmaceuticals Limited 802.8M 82 67 69 86 1
Immunovant, Inc. 802.7M 82 68 69 87 1
Gossamer Bio, Inc. 789.5M 82 71 73 88 1
Arcutis Biotherapeutics, Inc. 785.6M 82 67 68 89 1
PMV Pharmaceuticals, Inc. 772.4M 82 53 54 90 1
Design Therapeutics, Inc. 772.1M 97 63 66 91 1
Kiniksa Pharmaceuticals, Ltd. 763.3M 39 68 64 92 1
Chinook Therapeutics, Inc. 749.8M 76 49 50 93 1
Century Therapeutics, Inc. 745.4M 82 45 47 94 1
MeiraGTx Holdings plc 732.5M 50 71 69 95 1
Rubius Therapeutics, Inc. 705.4M 82 68 69 96 1
COMPASS Pathways plc 696.9M 82 50 51 97 1

Cash Flow Analysis

Probing the changes in the companys cash flow underscored the importance of certain key numbers that often have the most significant effect on company performance for the current market. First, analysis of BioNTech SE's flow of cash coming from operations, finance, and investments forecasts great overperformance concerning cash flow momentum. The flow of cash coming from operations, finance, and investments factors impact up to 1.0% of the probability that the company will over-perform its benchmark. Focusing on the companys net cash flow suggests impressive results in terms of free cash flow growth. In general, these factors influence around 8.2% of the chances of a company to over-perform in the upcoming quarter. Our rating of BioNTech SE's cash flow generated the total score of 95.

Parameter Value Change Score
Free Cashflow 4.92 352% 97
Cashflow 1,402.16 311% 93
* All values are TTM

The below chart describes BioNTech SE's performance as reflected on its cash flow with respect to its peers. While BioNTech SE received a cash flow score of 95 out of 100, the average of its peers stands on 67 out of 100.

  •  BNTX
  •  Peers average
Name Market Cap Cashflow Momentum Free Cashflow Growth Cash Flow mc_sort Hidden
Johnson & Johnson 438.5B 79 66 76 0 1
Pfizer Inc. 300.5B 73 88 78 1 1
AstraZeneca PLC 181.5B 76 59 71 2 1
Amgen Inc. 130.3B 51 56 53 3 1
Gilead Sciences, Inc. 86.6B 91 78 88 4 1
Moderna, Inc. 70.6B 87 84 86 5 1
Regeneron Pharmaceuticals, Inc. 64.6B 94 96 96 6 1
Vertex Pharmaceuticals Incorporated 58.7B 82 76 81 7 1
Biogen Inc. 33.9B 54 55 55 8 1
BeiGene, Ltd. 24.3B 73 57 69 9 1
Seagen Inc. 24.2B 51 40 48 10 1
Horizon Therapeutics Public Limited Company 20.0B 90 89 90 11 1
Alnylam Pharmaceuticals, Inc. 16.6B 53 61 56 12 1
Incyte Corporation 16.5B 85 82 85 13 1
BioMarin Pharmaceutical Inc. 15.8B 75 75 76 14 1
United Therapeutics Corporation 9.2B 53 55 54 15 1
Novavax, Inc. 7.0B 55 49 54 16 1
Neurocrine Biosciences, Inc. 6.9B 75 85 79 17 1
Ascendis Pharma A/S 6.7B 71 56 67 18 1
Mirati Therapeutics, Inc. 6.7B 75 77 76 19 1
Legend Biotech Corporation 6.2B 77 76 77 20 1
Natera, Inc. 5.8B 47 51 49 21 1
Arena Pharmaceuticals, Inc. 5.6B 66 58 64 22 1
Arrowhead Pharmaceuticals, Inc. 5.6B 67 40 59 23 1
Sarepta Therapeutics, Inc. 5.5B 79 82 80 24 1
Exelixis, Inc. 5.4B 71 84 76 25 1
Halozyme Therapeutics, Inc. 4.7B 85 92 88 26 1
Ultragenyx Pharmaceutical Inc. 4.5B 72 66 71 27 1
Vir Biotechnology, Inc. 4.4B 66 43 60 28 1
Ionis Pharmaceuticals, Inc. 4.3B 58 43 54 29 1
Blueprint Medicines Corporation 4.3B 61 38 55 30 1
Beam Therapeutics Inc. 4.2B 64 82 70 31 1
Denali Therapeutics Inc. 4.1B 75 55 70 32 1
Alkermes plc 4.0B 71 85 76 33 1
Apellis Pharmaceuticals, Inc. 3.7B 52 51 52 34 1
NantKwest, Inc. 3.6B 66 59 64 35 1
ACADIA Pharmaceuticals Inc. 3.5B 80 74 79 36 1
OPKO Health, Inc. 3.0B 45 46 46 37 1
PTC Therapeutics, Inc. 2.9B 69 48 63 38 1
Twist Bioscience Corporation 2.7B 93 92 94 39 1
Cytokinetics, Incorporated 2.7B 44 37 42 40 1
SpringWorks Therapeutics, Inc. 2.6B 59 52 57 41 1
Insmed Incorporated 2.6B 67 65 67 42 1
BioCryst Pharmaceuticals, Inc. 2.6B 67 76 71 43 1
ImmunityBio, Inc. 2.4B 64 50 61 44 1
Myriad Genetics, Inc. 2.1B 86 79 85 45 1
Recursion Pharmaceuticals, Inc. 2.1B 69 85 75 46 1
ChemoCentryx, Inc. 2.1B 72 58 68 47 1
Ironwood Pharmaceuticals, Inc. 1.8B 63 76 68 48 1
Turning Point Therapeutics, Inc. 1.8B 52 46 50 49 1
Global Blood Therapeutics, Inc. 1.8B 52 57 54 50 1
Revolution Medicines, Inc. 1.8B 73 63 70 51 1
BridgeBio Pharma, Inc. 1.7B 79 66 75 52 1
Agios Pharmaceuticals, Inc. 1.7B 76 59 71 53 1
Prothena Corporation plc 1.7B 69 97 78 54 1
Sana Biotechnology, Inc. 1.7B 60 85 69 55 1
Allogene Therapeutics, Inc. 1.7B 67 74 69 56 1
Instil Bio, Inc. 1.6B 56 82 64 57 1
Verve Therapeutics, Inc. 1.6B 59 92 69 58 1
IVERIC bio, Inc. 1.5B 45 58 49 59 1
Bicycle Therapeutics plc 1.4B 85 91 88 60 1
Erasca, Inc. 1.4B 42 86 56 61 1
Editas Medicine, Inc. 1.3B 69 77 72 62 1
Atara Biotherapeutics, Inc. 1.3B 60 65 62 63 1
Lyell Immunopharma, Inc. 1.3B 67 92 75 64 1
Prometheus Biosciences, Inc. 1.3B 59 82 67 65 1
Alector, Inc. 1.3B 67 96 77 66 1
ImmunoGen, Inc. 1.3B 56 71 61 67 1
FibroGen, Inc. 1.2B 90 83 89 68 1
C4 Therapeutics, Inc. 1.2B 67 83 72 69 1
Enanta Pharmaceuticals, Inc. 1.2B 90 92 91 70 1
Madrigal Pharmaceuticals, Inc. 1.2B 64 72 67 71 1
REGENXBIO Inc. 1.1B 73 61 70 72 1
Anavex Life Sciences Corp. 1.0B 94 93 94 73 1
Replimune Group, Inc. 998.4M 59 61 60 74 1
Vaxcyte, Inc. 974.7M 44 50 46 75 1
Crinetics Pharmaceuticals, Inc. 960.1M 54 61 56 76 1
Day One Biopharmaceuticals, Inc. 911.0M 59 92 69 77 1
Syndax Pharmaceuticals, Inc. 893.8M 64 63 64 78 1
AnaptysBio, Inc. 891.3M 84 95 88 79 1
Immunocore Holdings plc 889.6M 56 54 56 80 1
Inovio Pharmaceuticals, Inc. 881.5M 71 80 74 81 1
Sangamo Therapeutics, Inc. 877.0M 47 41 45 82 1
uniQure N.V. 860.5M 68 62 67 83 1
Kura Oncology, Inc. 848.6M 65 63 64 84 1
MacroGenics, Inc. 811.7M 83 77 82 85 1
Centessa Pharmaceuticals Limited 802.8M 55 43 52 86 1
Immunovant, Inc. 802.7M 66 77 70 87 1
Gossamer Bio, Inc. 789.5M 61 72 65 88 1
Arcutis Biotherapeutics, Inc. 785.6M 61 72 65 89 1
PMV Pharmaceuticals, Inc. 772.4M 75 77 76 90 1
Design Therapeutics, Inc. 772.1M 54 61 57 91 1
Kiniksa Pharmaceuticals, Ltd. 763.3M 83 74 81 92 1
Chinook Therapeutics, Inc. 749.8M 58 77 64 93 1
Century Therapeutics, Inc. 745.4M 62 89 70 94 1
MeiraGTx Holdings plc 732.5M 67 55 64 95 1
Rubius Therapeutics, Inc. 705.4M 62 64 64 96 1
COMPASS Pathways plc 696.9M 80 81 81 97 1

General & Ratios Analysis

Our cumulative analysis of the most critical factors in these reports informs our broader perspective of BioNTech SE's attractiveness for the upcoming quarter. Taking in consideration the company's metrics in relation to general factors forecasts uninspired performance with connection to macroeconomic environment. Moreover, diving into the company's health and sustainability suggests mediocre overperformance with respect to book value momentum. Typically, these factors will influence up to 16.2% of the chances of a company to beat its benchmark performance. Looking closer at analyzing their capital efficiency reveals modest results related to assets factors momentum. Historically, the capital efficiency factors will impact around 13.4% of a company's likelihood to over-perform during the coming quarters. Perhaps most unappreciated, our assessment of investors' interest shows slightly above average results in terms of return factors momentum. In general, these factors impact up to 2.1% of the likelihood that a company will over-perform its benchmark during the current market. Last, diving deeper into their capital efficiency found modest results related to assets factors momentum. The capital efficiency factors influence 13.4% of the likelihood that a company will beat its benchmark performance during the coming months. With all factors evaluated together, our bottom line evaluation of BioNTech SE's general factors and ratios deserved the total score of 69.

Parameter Value Change Score
Asset Turnover 1.76 15% 64
Price to Book 6.31 -25% 72
Return on Equity 155.47 16% 72
* All values are TTM

The below chart describes BioNTech SE's performance as reflected on its Financial Ratios with respect to its peers. While BioNTech SE received a Financial Ratios score of 69 out of 100, the average of its peers stands on 70 out of 100.

  •  BNTX
  •  Peers average
Name Market Cap Macro Environment Book Value Momentum Return Factors Momentum Assets Factors Momentum General Factors mc_sort Hidden
Johnson & Johnson 438.5B 58 74 67 69 73 0 1
Pfizer Inc. 300.5B 58 91 74 67 81 1 1
AstraZeneca PLC 181.5B 58 64 57 72 68 2 1
Amgen Inc. 130.3B 58 66 67 45 54 3 1
Gilead Sciences, Inc. 86.6B 58 80 81 63 75 4 1
Moderna, Inc. 70.6B 58 69 74 59 65 5 1
Regeneron Pharmaceuticals, Inc. 64.6B 58 82 66 57 69 6 1
Vertex Pharmaceuticals Incorporated 58.7B 58 83 67 64 74 7 1
Biogen Inc. 33.9B 58 56 63 84 73 8 1
BeiGene, Ltd. 24.3B 58 51 74 78 69 9 1
Seagen Inc. 24.2B 58 58 58 86 74 10 1
Horizon Therapeutics Public Limited Company 20.0B 58 87 57 54 68 11 1
Alnylam Pharmaceuticals, Inc. 16.6B 58 64 59 83 75 12 1
Incyte Corporation 16.5B 58 68 74 69 72 13 1
BioMarin Pharmaceutical Inc. 15.8B 58 73 42 79 74 14 1
United Therapeutics Corporation 9.2B 58 84 64 63 73 15 1
Novavax, Inc. 7.0B 58 71 56 85 79 16 1
Neurocrine Biosciences, Inc. 6.9B 58 73 84 84 86 17 1
Ascendis Pharma A/S 6.7B 58 70 75 62 68 18 1
Mirati Therapeutics, Inc. 6.7B 58 58 67 52 55 19 1
Legend Biotech Corporation 6.2B 58 72 56 87 81 20 1
Natera, Inc. 5.8B 58 63 77 40 51 21 1
Arena Pharmaceuticals, Inc. 5.6B 58 72 59 66 69 22 1
Arrowhead Pharmaceuticals, Inc. 5.6B 58 59 58 75 68 23 1
Sarepta Therapeutics, Inc. 5.5B 58 69 72 57 64 24 1
Exelixis, Inc. 5.4B 58 74 75 72 76 25 1
Halozyme Therapeutics, Inc. 4.7B 58 63 72 62 64 26 1
Ultragenyx Pharmaceutical Inc. 4.5B 58 55 70 86 75 27 1
Vir Biotechnology, Inc. 4.4B 58 66 76 92 85 28 1
Ionis Pharmaceuticals, Inc. 4.3B 58 55 70 60 59 29 1
Blueprint Medicines Corporation 4.3B 58 68 58 44 53 30 1
Beam Therapeutics Inc. 4.2B 58 63 76 50 57 31 1
Denali Therapeutics Inc. 4.1B 58 46 60 84 68 32 1
Alkermes plc 4.0B 58 69 56 81 75 33 1
Apellis Pharmaceuticals, Inc. 3.7B 58 62 55 53 55 34 1
NantKwest, Inc. 3.6B 59 40 61 96 72 35 1
ACADIA Pharmaceuticals Inc. 3.5B 58 67 72 55 62 36 1
OPKO Health, Inc. 3.0B 58 80 78 50 66 37 1
PTC Therapeutics, Inc. 2.9B 58 72 47 88 80 38 1
Twist Bioscience Corporation 2.7B 58 46 70 81 67 39 1
Cytokinetics, Incorporated 2.7B 58 63 45 53 53 40 1
SpringWorks Therapeutics, Inc. 2.6B 58 63 61 91 81 41 1
Insmed Incorporated 2.6B 58 62 59 85 76 42 1
BioCryst Pharmaceuticals, Inc. 2.6B 58 71 54 90 82 43 1
ImmunityBio, Inc. 2.4B 58 72 45 80 75 44 1
Myriad Genetics, Inc. 2.1B 58 71 99 44 61 45 1
Recursion Pharmaceuticals, Inc. 2.1B 58 45 73 86 71 46 1
ChemoCentryx, Inc. 2.1B 58 78 66 88 87 47 1
Ironwood Pharmaceuticals, Inc. 1.8B 58 70 58 55 61 48 1
Turning Point Therapeutics, Inc. 1.8B 58 45 61 81 65 49 1
Global Blood Therapeutics, Inc. 1.8B 58 56 64 82 72 50 1
Revolution Medicines, Inc. 1.8B 58 56 66 79 70 51 1
BridgeBio Pharma, Inc. 1.7B 58 71 58 76 74 52 1
Agios Pharmaceuticals, Inc. 1.7B 58 58 62 90 78 53 1
Prothena Corporation plc 1.7B 58 65 76 49 58 54 1
Sana Biotechnology, Inc. 1.7B 58 66 58 93 83 55 1
Allogene Therapeutics, Inc. 1.7B 58 44 65 92 73 56 1
Instil Bio, Inc. 1.6B 58 62 62 91 80 57 1
Verve Therapeutics, Inc. 1.6B 58 48 81 93 79 58 1
IVERIC bio, Inc. 1.5B 58 96 72 44 69 59 1
Bicycle Therapeutics plc 1.4B 58 94 72 67 82 60 1
Erasca, Inc. 1.4B 58 98 64 43 67 61 1
Editas Medicine, Inc. 1.3B 58 46 63 42 42 62 1
Atara Biotherapeutics, Inc. 1.3B 58 69 63 76 74 63 1
Lyell Immunopharma, Inc. 1.3B 58 44 74 81 68 64 1
Prometheus Biosciences, Inc. 1.3B 58 75 58 60 66 65 1
Alector, Inc. 1.3B 58 64 76 52 59 66 1
ImmunoGen, Inc. 1.3B 58 79 59 53 64 67 1
FibroGen, Inc. 1.2B 58 63 72 56 61 68 1
C4 Therapeutics, Inc. 1.2B 58 53 66 90 76 69 1
Enanta Pharmaceuticals, Inc. 1.2B 58 76 64 90 86 70 1
Madrigal Pharmaceuticals, Inc. 1.2B 58 58 62 88 76 71 1
REGENXBIO Inc. 1.1B 58 69 60 79 76 72 1
Anavex Life Sciences Corp. 1.0B 58 51 71 83 72 73 1
Replimune Group, Inc. 998.4M 58 61 64 81 74 74 1
Vaxcyte, Inc. 974.7M 58 60 64 81 74 75 1
Crinetics Pharmaceuticals, Inc. 960.1M 58 76 64 76 78 76 1
Day One Biopharmaceuticals, Inc. 911.0M 58 53 70 89 76 77 1
Syndax Pharmaceuticals, Inc. 893.8M 58 73 65 93 87 78 1
AnaptysBio, Inc. 891.3M 58 79 76 77 82 79 1
Immunocore Holdings plc 889.6M 58 68 60 80 76 80 1
Inovio Pharmaceuticals, Inc. 881.5M 58 43 58 82 64 81 1
Sangamo Therapeutics, Inc. 877.0M 58 46 60 79 64 82 1
uniQure N.V. 860.5M 58 48 75 78 68 83 1
Kura Oncology, Inc. 848.6M 58 60 65 76 70 84 1
MacroGenics, Inc. 811.7M 58 45 66 73 61 85 1
Centessa Pharmaceuticals Limited 802.8M 58 43 78 87 72 86 1
Immunovant, Inc. 802.7M 58 67 73 56 63 87 1
Gossamer Bio, Inc. 789.5M 58 72 61 88 83 88 1
Arcutis Biotherapeutics, Inc. 785.6M 58 54 61 92 76 89 1
PMV Pharmaceuticals, Inc. 772.4M 58 47 73 82 70 90 1
Design Therapeutics, Inc. 772.1M 58 62 60 92 80 91 1
Kiniksa Pharmaceuticals, Ltd. 763.3M 58 62 73 70 69 92 1
Chinook Therapeutics, Inc. 749.8M 58 67 76 70 72 93 1
Century Therapeutics, Inc. 745.4M 58 46 71 86 71 94 1
MeiraGTx Holdings plc 732.5M 58 73 60 89 84 95 1
Rubius Therapeutics, Inc. 705.4M 58 46 61 90 71 96 1
COMPASS Pathways plc 696.9M 58 64 74 87 80 97 1

This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.